SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Precigen, Inc. – ‘10-K’ for 12/31/23 – ‘EX-10.11’

On:  Tuesday, 3/19/24, at 4:48pm ET   ·   For:  12/31/23   ·   Accession #:  1356090-24-7   ·   File #:  1-36042

Previous ‘10-K’:  ‘10-K’ on 3/6/23 for 12/31/22   ·   Next & Latest:  ‘10-K/A’ on 4/29/24 for 12/31/23   ·   21 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/19/24  Precigen, Inc.                    10-K       12/31/23  117:21M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.18M 
 3: EX-10.10    Material Contract                                   HTML     46K 
 4: EX-10.11    Material Contract                                   HTML     48K 
 2: EX-10.9     Material Contract                                   HTML     42K 
 5: EX-21.1     Subsidiaries List                                   HTML     33K 
 6: EX-23.1     Consent of Expert or Counsel                        HTML     32K 
11: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     51K 
                Awarded Compensation                                             
 7: EX-31.1     Certification -- §302 - SOA'02                      HTML     37K 
 8: EX-31.2     Certification -- §302 - SOA'02                      HTML     37K 
 9: EX-32.1     Certification -- §906 - SOA'02                      HTML     34K 
10: EX-32.2     Certification -- §906 - SOA'02                      HTML     34K 
17: R1          Cover Page                                          HTML     98K 
18: R2          Audit Information                                   HTML     38K 
19: R3          Consolidated Balance Sheets                         HTML    149K 
20: R4          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
21: R5          Consolidated Statements of Operations               HTML    159K 
22: R6          Consolidated Statements of Operations               HTML     46K 
                (Parenthetical)                                                  
23: R7          Condensed Consolidated Statements of Comprehensive  HTML     57K 
                Income (Loss)                                                    
24: R8          Consolidated Statements of Shareholders' Equity     HTML    130K 
25: R9          Consolidated Statements of Cash Flows               HTML    165K 
26: R10         Consolidated Statements of Cash Flows               HTML     44K 
                (Reconciliation of Cash)                                         
27: R11         Consolidated Statement of Cash Flows                HTML     34K 
                (Parenthetical)                                                  
28: R12         Organization and Basis of Presentation              HTML     43K 
29: R13         Summary of Significant Accounting Policies          HTML    107K 
30: R14         Discontinued Operations                             HTML     88K 
31: R15         Investments in Joint Ventures                       HTML     41K 
32: R16         Collaboration and Licensing Revenue                 HTML     66K 
33: R17         Short-term and Long-term Investments                HTML     58K 
34: R18         Fair Value Measurements                             HTML     61K 
35: R19         Property, Plant and Equipment, Net                  HTML     49K 
36: R20         Goodwill and Intangible Assets, Net                 HTML     59K 
37: R21         Lines of Credit and Long-Term Debt                  HTML     50K 
38: R22         Income Taxes                                        HTML    121K 
39: R23         Shareholders' Equity                                HTML     50K 
40: R24         Share-Based Payments                                HTML     90K 
41: R25         Commitments and Contingencies                       HTML     41K 
42: R26         Operating Leases                                    HTML     63K 
43: R27         Segments                                            HTML    109K 
44: R28         Defined Contribution Plans                          HTML     35K 
45: R29         Summary of Significant Accounting Policies          HTML    148K 
                (Policies)                                                       
46: R30         Summary of Significant Accounting Policies          HTML     70K 
                (Tables)                                                         
47: R31         Discontinued Operations (Tables)                    HTML     85K 
48: R32         Collaboration and Licensing Revenue (Tables)        HTML     58K 
49: R33         Short-term and Long-term Investments (Tables)       HTML     59K 
50: R34         Fair Value Measurements (Tables)                    HTML     58K 
51: R35         Property, Plant and Equipment, Net (Tables)         HTML     48K 
52: R36         Goodwill and Intangible Assets, Net (Tables)        HTML     65K 
53: R37         Lines of Credit and Long-Term Debt (Tables)         HTML     42K 
54: R38         Income Taxes (Tables)                               HTML    125K 
55: R39         Shareholders' Equity (Tables)                       HTML     40K 
56: R40         Share-Based Payments (Tables)                       HTML     89K 
57: R41         Operating Leases (Tables)                           HTML     64K 
58: R42         Segments (Tables)                                   HTML    105K 
59: R43         Organization and Basis of Presentation -            HTML     63K 
                Additional Information (Details)                                 
60: R44         Summary of Significant Accounting Policies -        HTML     75K 
                Additional Information (Details)                                 
61: R45         Summary of Significant Accounting Policies -        HTML     43K 
                Rollforward of Allowance for Credit Losses                       
                (Details)                                                        
62: R46         Summary of Significant Accounting Policies -        HTML     56K 
                Estimated Useful Lives of Property, Plant and                    
                Equipment (Details)                                              
63: R47         Summary of Significant Accounting Policies -        HTML     60K 
                Summary of Assumptions Used in Option Pricing                    
                Model (Details)                                                  
64: R48         Summary of Significant Accounting Policies -        HTML     43K 
                Potentially Dilutive Securities Excluded from                    
                Calculation of Net Loss per Share (Details)                      
65: R49         Discontinued Operations - Narrative (Details)       HTML     65K 
66: R50         Discontinued Operations - Summary of Financial      HTML     75K 
                Results for Trans Ova (Details)                                  
67: R51         Discontinued Operations - Summary of Significant    HTML     59K 
                Non-Cash Items, Investments and Purchases of                     
                Property, Plant and Equipment on Cash Flows -                    
                Trans Ova (Details)                                              
68: R52         Discontinued Operations - Summary of Financial      HTML     48K 
                Results for MBP Titan (Details)                                  
69: R53         Discontinued Operations - Summary Of Significant    HTML     43K 
                Non-Cash Items, Investments and Purchases of                     
                Property, Plant and Equipment on Cash Flows - MBP                
                Titan (Details)                                                  
70: R54         Investments in Joint Ventures - Intrexon Energy     HTML     52K 
                Partners - Additional Information (Details)                      
71: R55         Investments in Joint Ventures - Intrexon Energy     HTML     52K 
                Partners II - Additional Information (Details)                   
72: R56         Investments in Joint Ventures - Interests in        HTML     42K 
                Intrexon Energy Partners and Intrexon Energy                     
                Partners II (Details)                                            
73: R57         Collaboration and Licensing Revenue - Summarized    HTML     51K 
                Collaboration and Licensing Revenues (Details)                   
74: R58         Collaboration and Licensing Revenue - Additional    HTML     48K 
                Information (Details)                                            
75: R59         Collaboration and Licensing Revenue - Summary of    HTML     46K 
                Deferred Revenue (Details)                                       
76: R60         Short-term and Long-term Investments - Summary of   HTML     55K 
                Amortized Cost, Gross Unrealized Gains and Losses                
                and Fair Value of Investments (Details)                          
77: R61         Short-term and Long-term Investments - Narrative    HTML     35K 
                (Details)                                                        
78: R62         Fair Value Measurements - Summary of Placement in   HTML     60K 
                the Fair Value Hierarchy of Financial Assets that                
                are Measured at Fair Value on a Recurring Basis                  
                (Details)                                                        
79: R63         Fair Value Measurements - Additional Information    HTML     39K 
                (Details)                                                        
80: R64         Property, Plant and Equipment, Net - Schedule of    HTML     57K 
                Property, Plant and Equipment (Details)                          
81: R65         Property, Plant and Equipment, Net - Additional     HTML     40K 
                Information (Details)                                            
82: R66         Goodwill and Intangible Assets, Net - Schedule of   HTML     45K 
                Changes in Carrying Amount of Goodwill (Details)                 
83: R67         Goodwill and Intangible Assets, Net - Additional    HTML     52K 
                Information (Details)                                            
84: R68         Goodwill and Intangible Assets, Net - Schedule of   HTML     47K 
                Intangible Assets (Details)                                      
85: R69         Goodwill and Intangible Assets, Net - Schedule of   HTML     48K 
                Definite-Lived Intangible Assets, Estimated Future               
                Amortization Expense (Details)                                   
86: R70         Lines of Credit and Long-Term Debt - Lines of       HTML     44K 
                Credit - Additional Information (Details)                        
87: R71         Lines of Credit and Long-Term Debt - Short-Term     HTML     67K 
                Debt and Convertible Debt - Additional Information               
                (Details)                                                        
88: R72         Lines of Credit and Long-Term Debt - Components of  HTML     48K 
                Interest Expense (Details)                                       
89: R73         Income Taxes - Components of Loss Before Income     HTML     42K 
                Taxes (Details)                                                  
90: R74         Income Taxes - Components of Income Tax Benefit     HTML     53K 
                (Details)                                                        
91: R75         Income Taxes - Schedule of Effective Income Tax     HTML     61K 
                Rate Reconciliation (Details)                                    
92: R76         Income Taxes - Schedule of Deferred Tax Assets and  HTML     75K 
                Liabilities (Details)                                            
93: R77         Income Taxes - Summary of Valuation Allowance       HTML     47K 
                (Details)                                                        
94: R78         Income Taxes - Additional Information (Details)     HTML     48K 
95: R79         Shareholders' Equity - Additional Information       HTML     54K 
                (Details)                                                        
96: R80         Shareholders' Equity - Components of Accumulated    HTML     54K 
                Other Comprehensive Income (Loss) (Details)                      
97: R81         Share-Based Payments - Schedule of Stock-based      HTML     45K 
                Compensation Expense (Details)                                   
98: R82         Share-Based Payments - Additional Information       HTML     89K 
                (Details)                                                        
99: R83         Share-Based Payments - Schedule of Stock Option     HTML     74K 
                Activity (Details)                                               
100: R84         Share-Based Payments - Schedule of Restricted       HTML     63K  
                Stock Unit Activity (Details)                                    
101: R85         Commitments and Contingencies - Contingencies -     HTML     42K  
                Additional Information (Details)                                 
102: R86         Operating Leases - Additional Information           HTML     40K  
                (Details)                                                        
103: R87         Operating Leases - Components of Lease Costs        HTML     41K  
                (Details)                                                        
104: R88         Operating Leases - Maturities of Lease Liabilities  HTML     56K  
                (Details)                                                        
105: R89         Operating Leases - Lease Terms and Discount Rates   HTML     37K  
                (Details)                                                        
106: R90         Operating Leases - Other Information (Details)      HTML     37K  
107: R91         Segments - Adjusted EBITDA by Reportable Segment    HTML     40K  
                (Details)                                                        
108: R92         Segments - Reconciliation of Net Loss Before        HTML     85K  
                Income Taxes (Details)                                           
109: R93         Segments - Revenues by Reportable Segment           HTML     43K  
                (Details)                                                        
110: R94         Segments - Additional Information (Details)         HTML     50K  
111: R95         Segments - Goodwill (Details)                       HTML     51K  
112: R96         Defined Contribution Plans - Additional             HTML     34K  
                Information (Details)                                            
114: XML         IDEA XML File -- Filing Summary                      XML    216K  
117: XML         XBRL Instance -- pgen-20231231_htm                   XML   2.17M  
113: EXCEL       IDEA Workbook of Financial Report Info              XLSX    206K  
13: EX-101.CAL  XBRL Calculations -- pgen-20231231_cal               XML    286K 
14: EX-101.DEF  XBRL Definitions -- pgen-20231231_def                XML   1.00M 
15: EX-101.LAB  XBRL Labels -- pgen-20231231_lab                     XML   1.93M 
16: EX-101.PRE  XBRL Presentations -- pgen-20231231_pre              XML   1.46M 
12: EX-101.SCH  XBRL Schema -- pgen-20231231                         XSD    221K 
115: JSON        XBRL Instance as JSON Data -- MetaLinks              648±   986K  
116: ZIP         XBRL Zipped Folder -- 0001356090-24-000007-xbrl      Zip   3.11M  


‘EX-10.11’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
  pgen-20231231xexx1011  
Privileged and Confidential 1 \\NORTHVA - 035885/000004 - 1092466 v5 Continuing Employment Agreement This Continuing Employment Agreement (this “Agreement”) is made as of xxxxxx x, 2024 between Precigen, Inc. (the “Company”) and [name] (the “Employee”). WHEREAS, the Employee is an employee of the Company and has been important in developing and expanding the business and operations of the Company, and possesses valuable knowledge and skills with respect to the Company; WHEREAS, the Company wishes to encourage the Employee’s continued employment with and dedication to the Company; and WHEREAS, the parties desire to enter into this Agreement setting forth the terms and conditions for the payment of compensation to the Employee in the event of a termination of the Employee’s employment during the term of this Agreement; NOW, THEREFORE, in consideration of the foregoing, the mutual covenants and agreements of the parties contained herein and other good and valuable consideration, the receipt of which is hereby acknowledged, the parties agree as follows: 1. The Company’s Obligations Upon Termination. Other than as specifically set forth or referenced in this Agreement, the Employee shall not be entitled to any compensation or other benefits on or after termination of employment. (a) Death. If the Employee’s employment ends as a result of death, the Company shall pay to the Employee’s legal representative or estate, as applicable, the Accrued Benefits, and no other amount. (b) Termination by the Company for Cause or Disability; Termination by the Employee without Good Reason. If the Company terminates the Employee’s employment for Cause or because of Disability, or the Employee terminates Employee’s employment other than for Good Reason, the Company shall pay to the Employee the Accrued Benefits, and no other amount. (c) Termination by the Company without Cause; Termination by the Employee for Good Reason. If the Company terminates the Employee’s employment other than for Cause or the Employee terminates the Employee’s employment for Good Reason, then, in addition to the Accrued Benefits, the Company shall pay or provide to the Employee only the following amounts, which are referred to in this Agreement as the “Severance Benefits”: (i) The Company shall pay to the Employee a gross amount equal to twelve (12) months of the Employee’s then-current base salary (or, in the event of a material reduction of the Employee’s base salary giving rise to Good Reason, the Employee’s pre- reduction base salary). (ii) If the Employee is eligible for and timely elects COBRA health care continuation coverage from the Company, the Company shall pay or reimburse the full premium cost of such coverage (at the same level of coverage that Employee had as of the Employee’s termination date) until the earlier of (x) twelve (12) months after the Employee’s termination date; or (y) the time at which the Employee becomes eligible to receive health care


 
Privileged and Confidential 2 \\NORTHVA - 035885/000004 - 1092466 v5 coverage from a subsequent employer or otherwise becomes ineligible for COBRA health care continuation coverage from the Company. (d) Deductions/Withholding. Any payments to the Employee pursuant to this Agreement shall be less applicable deductions and withholding as determined by the Company. (e) Timing of Payment of Accrued Benefits. The Company shall pay to the Employee (or to the Employee’s legal representative or estate if termination is because of death) the Accrued Benefits at the time such payments would otherwise be due under the Company’s normal payroll practices, applicable Company policies or plans, and as provided by applicable law. (f) Requirement of General Release; Timing of Payment of the Separation Payment. As a condition to receiving the Severance Benefits, the Employee must execute and deliver a general release of claims in a form acceptable to the Company (the “Release”) within 60 days of the Employee’s termination date, provided that all revocation periods applicable to the Release will have expired within 60 days of the Employee’s termination date. The Severance Benefits shall be paid or provided over an eighteen (18) month period, in regular installments in accordance with the Company’s general payroll practices, beginning on the first payroll period on or following the 60th day after the Employee’s termination date, provided that the Release has become irrevocable prior to the first payment date. (g) Section 409A Savings Provisions. It is intended that this Agreement and the payments and benefits provided under this Agreement shall comply with or be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended and the regulations and other guidance issued thereunder (collectively, “Section 409A”). Notwithstanding any other provision of this Agreement, payment provided under this Agreement may only be made upon an event and in a manner that complies with Section 409A or an applicable exemption. Specifically, any taxable benefits or payments provided under this Agreement are intended to be separate payments that qualify for the “short term deferral” exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the separation pay exceptions to Section 409A, to the maximum extent possible. Whenever any payment is to be made within a specified period of time under this Agreement, the exact timing of payment within such period shall be determined in the sole discretion of the Company. Notwithstanding anything to the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Employee on account of non-compliance with Section 409A. (i) Separation from Service. The Employee will be deemed to have a termination of employment for purposes of determining the timing of any payments or benefits hereunder that are classified as nonqualified deferred compensation only upon a “separation from service” within the meaning of Section 409A. (ii) Specified Employee Provisions. Notwithstanding any other provision of this Agreement to the contrary, if at the time of the Employee’s separation from service to the Company, (a) the Employee is a specified employee (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time), and (b) the Company makes a good faith determination that an amount payable on account of such separation from service to the Employee constitutes nonqualified deferred


 
Privileged and Confidential 3 \\NORTHVA - 035885/000004 - 1092466 v5 compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A (the “Delay Period”), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first payroll period after such Delay Period (or the first payroll period following the Employee’s death, if earlier), without interest thereon. (iii) Expense Reimbursements. To the extent required by Section 409A, any amount that the Employee is entitled to be reimbursed under this Agreement will be reimbursed to the Employee as promptly as practical and in any event not later than the last day of the calendar year after the calendar year in which the expenses are incurred. Any right to reimbursement or in-kind benefits will not be subject to liquidation or exchange for another benefit, and the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any taxable year will not affect the amount of expenses eligible for reimbursement, or in- kind benefits provided, in any other taxable year. (h) No Further Obligations. Except as set forth in this Agreement, the Company shall have no further obligation to the Employee under this Agreement upon the termination of the Employee’s employment. 2. Definitions. (a) “Accrued Benefits” means (i) the Employee’s base salary through the termination date not yet paid; (ii) any amounts or benefits owing to the Employee or to the Employee’s beneficiaries under the then-applicable benefit plans of the Company; and (iii) any amounts owing to the Employee for reimbursement of expenses properly incurred by the Employee prior to the termination date and which are reimbursable in accordance with Company policy. (b) “Cause” means any one of the following events: (1) material failure to observe and comply with any of the Company’s material written policies, including without limitation its policies prohibiting harassment (sexual or otherwise) and discrimination and its policies regarding equal employment opportunity and maintenance of a drug-free work place, to the satisfaction of the Company; (2) continued failure to substantially perform material duties with the Company; (3) willful failure to carry out, or comply with, in any material respect any lawful and reasonable written directive of the Company, which is not cured within twenty (20) calendar days after receipt by the Employee of notice of such failure; (4) commission of any act or omission that results in, or that may reasonably be expected to result in, a conviction, plea of no contest or imposition of unadjudicated probation for any felony or any crime involving moral turpitude; (5) commission of any act or omission that results in the Employee’s incarceration in a federal, state, or local jail or prison; (6) commission of any act of dishonesty, illegal conduct, fraud, embezzlement, misappropriation, material misconduct, or breach of fiduciary duty either (x) against the Company or any of its parent, subsidiary, or affiliate entities (collectively, “Affiliates”) (or any predecessor thereto or successor thereof) or (y) which is or which is reasonably expected to be materially injurious to the Company or its Affiliates; or (7) material or willful breach of any agreement (including this Agreement) between the Employee and the Company, which is not cured within twenty (20) calendar days after receipt by the Employee of written notice of such breach. (c) “Disability” means an impairment or other issue that prevents the Employee from substantially performing the duties and responsibilities of the Employee’s


 
Privileged and Confidential 4 \\NORTHVA - 035885/000004 - 1092466 v5 employment for a period of more than three consecutive months or for periods aggregating more than twenty-six (26) weeks in any one-year period. The Employee agrees, that in the event of any dispute as to whether a Disability exists and if requested by the Company, to submit to a physical examination by a licensed physician selected by mutual agreement between the Company and the Employee, the cost of such examination to be paid by the Company. The written medical opinion of such physician shall be conclusive and binding upon the parties as to whether a Disability exists and the date when such Disability arose. This definition of “Disability” shall be interpreted and applied so as to comply with the provisions of the Americans with Disabilities Act (to the extent that it is applicable) and any applicable state or local laws. (d) “Good Reason” means (1) a material diminution in the Employee’s authority, duties or responsibilities; (2) a material reduction in the Employee’s base salary (other than a general reduction in compensation applying to other similarly-situated employees of the Company); or (3) the relocation of the primary office from which the Employee is required to work to a location more than fifty (50) miles from the current office location where the Employee primarily works, which relocation increases the Employee’s one-way commute. No event or condition shall constitute “Good Reason” unless the Employee provides the Company with written notice of the event or condition the Employee alleges to be Good Reason within thirty (30) days after such event or condition first occurs. The termination shall not become effective unless the Company fails to cure such event or condition constituting Good Reason within thirty (30) days following the Company’s receipt of such notice. The Employee must terminate employment within thirty (30) days after the end of the cure period in order for the termination to be for Good Reason. 3. Restrictive Covenants. (a) Confidentiality Agreement. As a condition of being eligible to receive the Severance Benefits, the Employee reaffirms and shall continue to comply with the Confidentiality and Proprietary Rights Agreement the Employee signed on [date] (the “Confidentiality Agreement”). (b) Non-Disparagement. During the Employee’s employment and after it ends (regardless of the reason), the Employee shall not make to any person or entity any disparaging, defamatory, or derogatory statements or comments about the Company or any of its directors, officers, employees, products, or services. (c) Survival of Provisions. The Employee’s obligations contained in this Section 3 (including in the Confidentiality Agreement) shall survive the termination or expiration of the Employee’s employment with the Company. 4. Miscellaneous. (a) Governing Law. This Agreement shall be governed by and construed under the laws of Maryland, without regard to its conflicts of law principles. Suit to enforce any provision of this Agreement or to obtain any remedy with respect hereto may be brought in a court in the State of Maryland and for this purpose I expressly consent to the jurisdiction of said courts. (b) Entire Agreement. This Agreement contains the entire understanding of the parties as to its subject matter, and terminates and supersedes any and all prior agreements


 
Privileged and Confidential 5 \\NORTHVA - 035885/000004 - 1092466 v5 and understandings between the parties with respect to that subject matter, whether oral or written. For the avoidance of doubt, other than as specified in this Agreement, the Employee is not entitled to any “severance” or similar payments from the Company, whether pursuant to another agreement, plan, or policy of the Company or otherwise. For the further avoidance of doubt, nothing in this Agreement terminates or supersedes the terms of the Confidentiality Agreement. This Agreement may not be modified in any respect except by a writing executed by each party hereto. (c) Severability. In the event a court or other adjudicator of competent jurisdiction determines that any portion of this Agreement is invalid or unenforceable, only the portions that are invalid or unenforceable shall be stricken. (d) Headings. Section headings in this Agreement are included for convenience of reference only and shall not constitute part of this Agreement for any other purpose. (e) Counterparts and Digital Signature. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. In the event that any signature is delivered via e-mail transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such digital signature page were an original signature. (f) Assignment. The Employee may not assign or transfer this Agreement or any rights or obligations hereunder. The Company may assign this Agreement without the written consent of the Employee. (g) Confidentiality. The Employee shall not disclose or discuss this Agreement or its terms with any person, organization, or entity, other than the Employee’s immediate family, accountants, or attorneys, and agrees that any subsequent disclosure by such parties will be deemed a disclosure by the Employee. [Signature Page Follows]


 
Privileged and Confidential 6 \\NORTHVA - 035885/000004 - 1092466 v5 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized officer and the Employee has hereunto signed this Agreement on the date first above written. PRECIGEN, INC. ______________________________ By: Helen Sabzevari Title: Chief Executive Officer EMPLOYEE ______________________________ [Name]


 

21 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/09/23  Precigen, Inc.                    10-Q        6/30/23   93:17M
 7/06/23  Precigen, Inc.                    S-8         7/06/23    5:212K                                   Davis Polk & … LLP 01/FA
11/09/20  Precigen, Inc.                    10-Q        9/30/20  117:12M
 6/22/20  Precigen, Inc.                    S-3                    7:747K                                   Donnelley … Solutions/FA
 6/19/20  Precigen, Inc.                    8-K:5,9     6/19/20   11:175K                                   Donnelley … Solutions/FA
 6/04/20  Precigen, Inc.                    8-K:5,9     6/03/20   11:295K                                   Donnelley … Solutions/FA
 5/11/20  Precigen, Inc.                    10-Q        3/31/20  111:10M
 3/02/20  Precigen, Inc.                    10-K       12/31/19  141:33M                                    Workiva Inc Wde… FA01/FA
 2/04/20  Precigen, Inc.                    8-K:2,5,8,9 1/30/20   13:379K                                   Donnelley … Solutions/FA
 1/07/20  Precigen, Inc.                    8-K:5,9     1/01/20   11:240K                                   Donnelley … Solutions/FA
 8/09/19  Precigen, Inc.                    10-Q        6/30/19  116:12M
 6/12/19  Precigen, Inc.                    8-K:5,9     6/12/19    2:43K                                    Donnelley … Solutions/FA
 5/09/19  Precigen, Inc.                    10-Q        3/31/19  109:8.9M
 6/08/18  Precigen, Inc.                    8-K:5,9     6/07/18    2:36K                                    Donnelley … Solutions/FA
 3/01/18  Precigen, Inc.                    10-K       12/31/17  138:16M
 6/30/17  Precigen, Inc.                    8-K:5,9     6/28/17    2:35K                                    Donnelley … Solutions/FA
 6/13/16  Precigen, Inc.                    8-K:5,9     6/09/16    2:29K                                    Donnelley … Solutions/FA
 6/17/15  Precigen, Inc.                    8-K:5,9     6/11/15    3:101K                                   Donnelley … Solutions/FA
 1/14/15  Precigen, Inc.                    8-K:1,3,9   1/09/15    6:489K                                   Donnelley … Solutions/FA
 6/13/14  Precigen, Inc.                    8-K:5,9     6/09/14    5:407K                                   Donnelley … Solutions/FA
 7/29/13  Precigen, Inc.                    S-1/A                 15:5.3M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001356090-24-000007   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 9:43:23.3am ET